Erectile Dysfunction in Men With and Without Diabetes Mellitus: a Comparative Study

Bancroft, John; Gutiérrez, Pedro Conthe

doi:10.1002/(sici)1096-9136(199601)13:1<84::aid-dia16>3.3.co;2-1

Cited by 11 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, ED can be caused by neurologic, vascular, endocrinologic or psychological factors 4–6 . Diabetes mellitus (DM) is also a well known cause of ED 7,8 . Furthermore, glycemic control is known to influence erectile function in patients with DM.…”

Section: Introductionmentioning

confidence: 99%

Erectile dysfunction in hemodialysis patients with diabetes mellitus: Association with age and hemoglobin A1c levels

et al. 2004

View full text Add to dashboard Cite

Aim : Erectile dysfunction (ED) is common in patients with diabetes mellitus (DM) as well as those undergoing hemodialysis (HD). The purpose of this study is to investigate the frequency and severity of ED in HD patients with DM and those without DM. In addition, we examined the relationship between erectile function and several risk factors, including presence of DM and hemoglobin A1c levels in HD patients.Methods : This study involved 180 patients on HD, including 66 HD patients with DM (DM-HD) and 114 patients without DM (non-DM-HD). We evaluated erectile function using an abridged fiveitem version of the international index of erectile function (IIEF-5). Logistic regression analysis was used to investigate the relationship between presence of ED and several risk factors. Results : The total score of IIEF-5 in DM-HD patients (9.5 ± 4.2) was significantly lower than in non-DM-HD patients (13.5 ± 5.7). The prevalence of severe ED was 42.4% and 18.4% in DM-HD patients and non-DM-HD patients, respectively. Age, cardiovascular disease history, and DM were identified as independent risk factors for the presence of ED. Furthermore, age and elevated hemoglobin A1c levels were identified as independent risk factors for the presence of severe ED. Conclusion : DM-HD patients are more likely to have ED, and particularly severe forms of ED, than non-DM-HD patients. DM and elevated hemoglobin A1c levels were associated with the presence of ED or severe ED, respectively. Aging was identified as an independent factor in both ED and severe ED.

show abstract

Section: Introductionmentioning

confidence: 99%

Erectile dysfunction in hemodialysis patients with diabetes mellitus: Association with age and hemoglobin A1c levels

et al. 2004

View full text Add to dashboard Cite

show abstract

“…В подобном исследовании Bancroft и соавт. (1996) тот же показатель составил 35-55% [7]. По данным ГУ ЭНЦ (2005) распространенность ЭД среди больных СД1 и СД2 составила 38,7% и 66,2% соответственно, превышая таковую среди мужчин без диабета более чем в 3 раза [8].…”

Section: эректильная дисфункцияunclassified

Specific features of urogenital disorders in patents with diabetes mellitus

Роживанов¹,

Акимова²,

Дубский³

et al. 2009

Diabetes mellitus

View full text Add to dashboard Cite

о данным Всемирной организации здравоохранения в настоящее время на планете насчитывается около 220 млн. больных СД, и их число прогрессивно растет [1]. СД оказывает негативное влияние практически на все системы организма человека, в том числе и мочеполовую. С одной стороны, вследствие декомпенсации углеводного обмена у пациентов с СД развиваются нейропатия и васкулопатия, приводящие, прежде всего к функциональным нарушениям, с другой-СД является фоном для развития инфекционно-воспалительных заболеваний мочеполовой системы. К типичным нейрогенным и васкулогеным осложнениям СД относятся эректильная дисфунк ция (ЭД), нарушения эякуляции и диабетическая цистопатия. К инфекционно-воспалительным заболеваниям, развивающимся на фоне СД, относятся пиелонефрит, цистит и баланопостит.

show abstract

“…J. Bancroft et al (1996) оценили частоту ЭД при СД 1-го и 2-го типов соответственно в 35 и 59 % [4].…”

Section: Introductionunclassified

Efficacy of Tadalafil-SZ in the treatment of erectile dysfunction in patients with type 2 diabetes mellitus and with prediabetes

et al. 2019

View full text Add to dashboard Cite

The aim of the study was to evaluate the effectiveness of Tadalafil-SZ in treatment of erectile dysfunction in men suffering from type 2 diabetes mellitus or prediabetes. Two patient groups of thirty people with type 2 diabetes mellitus and prediabetes were identified. Patients mean age was 52.2 3.4 years and 48.5 2.8 years in groups with type 2 diabetes mellitus and prediabetes respectively. All patients suffered from erectile dysfunction, which significantly reduced their quality of life. To assess the erectile function, the ICEF (International Index of Erectile Function) and QoL (Quality of Life) questionnaires were used. Patients with prediabetes took Tadalafil-SZ 5 mg once a day for 3 months and patients with type 2 diabetes mellitus took Tadalafil-SZ 20 mg 2 times a week (Monday and Thursday) for 3 months as a treatment for erectile dysfunction. Results of this study showed that the administration of Tadalafil-SZ not only led to a significant improvement in the quality of life, a significant reduction in weight, body mass index, waist size in patients of both groups, but also led to a glycated hemoglobin level normalization without increasing the dose of glucose-lowering therapy in patients with uncomplicated type 2 diabetes mellitus and a pronounced decrease in morning insulin levels measured in the blood in patients with prediabetes. Almost half of patients in both groups increased testosterone blood level. According to the ICEF questionnaire, erectile function was significantly improved: in the group of patients with prediabetes: the ICEF-5 index prior to taking Tadalafil-SZ averaged 18.68 points (mild ED) whereas after taking the drug, a statistically significant increase in the ICEF index to an average of 23.02 points (p 0.05) was observed, which indicates the absence of erectile dysfunction in this group of patients during intake of Tadalafil-SZ. In the 2nd group of patients (with type 2 diabetes mellitus), the ICEF-5 index before treatment averaged 12.18 points, which reflects the average degree of erectile dysfunction, and at the end of the study there was a statistically significant increase in the ICEF-5 index to 18.44 points on average, which indicates a decrease in the severity of erectile dysfunction from moderate to mild (p 0.05). Overall Tadalafil-SZ is an effective treatment for erectile dysfunction in both patients with prediabetes and patients with type 2 diabetes mellitus.

show abstract

Erectile Dysfunction in Men With and Without Diabetes Mellitus: a Comparative Study

Cited by 11 publications

References 0 publications

Erectile dysfunction in hemodialysis patients with diabetes mellitus: Association with age and hemoglobin A1c levels

Erectile dysfunction in hemodialysis patients with diabetes mellitus: Association with age and hemoglobin A1c levels

Specific features of urogenital disorders in patents with diabetes mellitus

Efficacy of Tadalafil-SZ in the treatment of erectile dysfunction in patients with type 2 diabetes mellitus and with prediabetes

Contact Info

Product

Resources

About